City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 822,840 shares. Based on an average daily volume of 361,905 shares, the short-interest ratio is presently 2.3 days. Approximately 1.6% of the company’s shares are sold short.
City Therapeutics Stock Performance
Shares of City Therapeutics stock traded down $0.88 on Friday, hitting $18.10. 482,372 shares of the company traded hands, compared to its average volume of 338,021. City Therapeutics has a 12-month low of $15.81 and a 12-month high of $23.88.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on CTY shares. Jefferies Financial Group initiated coverage on City Therapeutics in a research report on Tuesday, November 10th. They set a “buy” rating and a $32.00 price objective for the company. Oppenheimer assumed coverage on City Therapeutics in a report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 target price on the stock. Zacks Research initiated coverage on shares of City Therapeutics in a research report on Wednesday. They issued a “hold” rating for the company. Stifel Nicolaus started coverage on shares of City Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $34.00 price target for the company. Finally, Wall Street Zen upgraded shares of City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, City Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $37.33.
Check Out Our Latest Report on CTY
Insiders Place Their Bets
In other news, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the company’s stock in a transaction dated Monday, October 19th. The shares were acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the transaction, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. The trade was a 1.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Nelsen bought 170,000 shares of the business’s stock in a transaction on Monday, October 19th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the purchase, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.
About City Therapeutics
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.
Further Reading
- Five stocks we like better than City Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
